MA54877A - Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur - Google Patents

Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur

Info

Publication number
MA54877A
MA54877A MA054877A MA54877A MA54877A MA 54877 A MA54877 A MA 54877A MA 054877 A MA054877 A MA 054877A MA 54877 A MA54877 A MA 54877A MA 54877 A MA54877 A MA 54877A
Authority
MA
Morocco
Prior art keywords
psychological
behavioral
cognitive
compositions
treatment
Prior art date
Application number
MA054877A
Other languages
English (en)
Inventor
Judith Blumstock
William J Tyler
Original Assignee
Diamond Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Diamond Therapeutics Inc filed Critical Diamond Therapeutics Inc
Publication of MA54877A publication Critical patent/MA54877A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/572—Five-membered rings
    • C07F9/5728—Five-membered rings condensed with carbocyclic rings or carbocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/48—Ergoline derivatives, e.g. lysergic acid, ergotamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/5415—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with carbocyclic ring systems, e.g. phenothiazine, chlorpromazine, piroxicam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
    • A61K36/258—Panax (ginseng)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
    • A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Hospice & Palliative Care (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Biotechnology (AREA)
  • Medical Informatics (AREA)
  • Emergency Medicine (AREA)
  • Microbiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Botany (AREA)
  • Biophysics (AREA)
  • Dispersion Chemistry (AREA)
  • Addiction (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
MA054877A 2019-01-30 2020-01-29 Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur MA54877A (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962799010P 2019-01-30 2019-01-30
US201962798998P 2019-01-30 2019-01-30

Publications (1)

Publication Number Publication Date
MA54877A true MA54877A (fr) 2021-12-08

Family

ID=71841404

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054877A MA54877A (fr) 2019-01-30 2020-01-29 Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur

Country Status (12)

Country Link
US (4) US20220096504A1 (fr)
EP (1) EP3917537A4 (fr)
JP (2) JP2022523700A (fr)
KR (1) KR20210134313A (fr)
CN (1) CN114040767A (fr)
AU (2) AU2020215150B8 (fr)
BR (1) BR112021014750A2 (fr)
CA (1) CA3127854A1 (fr)
IL (1) IL285186A (fr)
MA (1) MA54877A (fr)
MX (2) MX2021009037A (fr)
WO (1) WO2020157569A1 (fr)

Families Citing this family (83)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL311984A (en) 2016-07-07 2024-06-01 Hughes Howard Med Inst Modified ligand-gated ion channels and methods of use
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
CN111556751B (zh) 2017-11-10 2024-07-12 霍华休斯医学研究院 经修饰的配体门控的离子通道及使用方法
MX2021009037A (es) 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
US12616706B2 (en) * 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
US20210023052A1 (en) * 2019-07-23 2021-01-28 Caamtech Llc Compositions containing toad secretion compounds
JP2022550463A (ja) 2019-10-01 2022-12-01 エンピリアン ニューロサイエンス， インコーポレイテッド トリプタミン発現を調整する真菌の遺伝子操作
CN114650809A (zh) 2019-10-03 2022-06-21 斯塔顿治疗公司 屈大麻酚的透皮递送
US12409131B2 (en) 2019-10-03 2025-09-09 Pike Therapeutics Usa, Inc. Transdermal delivery of dronabinol
US12016829B2 (en) 2019-10-11 2024-06-25 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12186280B2 (en) 2019-10-11 2025-01-07 Pike Therapeutics Inc. Pharmaceutical composition and method for treating seizure disorders
US12268699B2 (en) 2019-10-14 2025-04-08 Pike Therapeutics Inc. Transdermal delivery of tetrahydrocannabinol
JP2022551730A (ja) 2019-10-14 2022-12-13 パイク セラピューティクス，インコーポレイテッド カンナビジオールの経皮送達
US12121617B2 (en) 2019-10-14 2024-10-22 Pike Therapeutics Inc. Transdermal delivery of cannabidiol
WO2021072530A1 (fr) * 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Formulations à libération contrôlée d'agents dérivés de psilocybes et leur procédé d'utilisation, et procédés et compositions pour traiter une lésion cérébrale traumatique légère avec un syndrome de stress post-traumatique
US20230021957A1 (en) * 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
US20210220336A1 (en) * 2020-01-22 2021-07-22 Clexio Biosciences Ltd. Topical detomidine formulations
AU2021215709A1 (en) 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
MX2022009527A (es) 2020-02-04 2022-11-16 Mindset Pharma Inc Derivados de la psilocina como agentes psicodelicos serotoninergicos para el tratamiento de trastornos del snc.
US20240277736A1 (en) * 2020-04-17 2024-08-22 Revive Therapeutics Ltd Use of psilocybin in the treatment of neurological brain injury and migraines
AU2021267101B2 (en) 2020-05-05 2024-03-28 Universitätsspital Basel MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
IL297861A (en) 2020-05-08 2023-01-01 Psilera Inc Novel compositions of matter and pharmaceutical compositions
IL312785B2 (en) 2020-05-19 2026-06-01 Cybin Irl Ltd Deuterated tryptamine derivatives and methods of use
WO2021243460A1 (fr) * 2020-06-03 2021-12-09 Neonmind Biosciences Inc. Méthode thérapeutique de perte de poids
WO2022023812A1 (fr) * 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Agonistes de récepteur 5-ht à libération prolongée pour des affections neurologiques
US20220062310A1 (en) * 2020-09-03 2022-03-03 Yale University Psilocybin in patients with obsessive-compulsive disorder
US20230364115A1 (en) * 2020-10-01 2023-11-16 Mydecine Innovations Group Inc. Novel psychedelic compositions, delivery systems and therapeutic uses thereof
WO2022079574A1 (fr) * 2020-10-12 2022-04-21 Goodcap Pharmaceuticals Ltd. Compositions pour la réduction de l'inflammation dans le but d'améliorer ou d'entretenir la santé mentale ou physique
WO2022094054A1 (fr) * 2020-10-28 2022-05-05 Mydecine Innovations Group Inc. Nouvelles formulations de composés fongiques et leurs méthodes d'utilisation thérapeutiques
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
WO2022115798A2 (fr) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions et méthodes de traitement de la migraine
WO2022115796A1 (fr) * 2020-11-30 2022-06-02 Wesana Health Inc. Compositions et méthodes de traitement de pathologies neurologiques
CA3201913A1 (fr) 2020-12-09 2022-06-16 Andrew R. Chadeayne Tryptamines de dialkyle et leurs utilisations therapeutiques
CA3113240C (fr) 2020-12-28 2023-09-05 Psilo Scientific Ltd. Composition d'alcaloide psychoactif transmucosal et preparation connexe
EP4277894A1 (fr) 2021-01-15 2023-11-22 Beckley Psytech Limited Analogues de la tryptamine
EP4126857A1 (fr) 2021-01-15 2023-02-08 Beckley Psytech Limited Analogues d'ergoline
US20220265601A1 (en) * 2021-02-10 2022-08-25 David Alan Heldreth, JR. Methods of use and formulations of allosteric modulators of the serotonin, dopamine and other receptor systems for medical, recreational, religious, research and other uses.
US11312684B1 (en) 2021-02-10 2022-04-26 Eleusis Therapeutics Us, Inc. Pharmaceutically acceptable salts of psilocin and uses thereof
US20220273628A1 (en) * 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
US20220370413A1 (en) * 2021-03-06 2022-11-24 Mind Medicine, Inc. Formulations of psilocin that have enhanced stability
EP4304603A4 (fr) * 2021-03-08 2025-01-22 Diamond Therapeutics Inc. Titrage d'agonistes du récepteur sérotoninergique
WO2022204323A1 (fr) * 2021-03-24 2022-09-29 The Trustees Of Columbia University In The City Of New York Analogues d'ariadne non hallucinogènes pour le traitement de troubles neurologiques et psychiatriques
MX2023011326A (es) * 2021-03-30 2023-10-03 Compass Pathfinder Ltd Composiciones de psilocibina, metodos para prepararlas y metodos de uso de estas.
KR20240006525A (ko) * 2021-03-31 2024-01-15 라이프 씨에이치엔지 엘엘씨 환각제의 치료적 투여를 위한 경피 시스템, 제제 및 방법
WO2022221554A2 (fr) * 2021-04-16 2022-10-20 Callitas Health Inc. Compositions et procédés pour l'administration de psilocine et de promédicaments de celle-ci
WO2022221942A1 (fr) * 2021-04-19 2022-10-27 Betterlife Pharma Inc. Prévention du détournement de médicaments
EP4329759A4 (fr) * 2021-04-30 2025-07-16 Mind Medicine Inc Formes cristallines de sels de lsd
EP4333979A4 (fr) * 2021-05-03 2025-01-15 Mind Medicine, Inc. Procédé de titrage de doses d'agents psychédéliques
WO2022235514A1 (fr) * 2021-05-04 2022-11-10 Mind Medicine, Inc. Administration de psychotropes par liposome
WO2022261058A1 (fr) * 2021-06-07 2022-12-15 University Of Mississippi Procédés de distribution pulsée d'agents bioactifs
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy
GB202109023D0 (en) * 2021-06-23 2021-08-04 Ldn Pharma Ltd Compositions comprising an agonist of 5-hydroxytryptamine (5-ht) receptor subtype 3
US20240366638A1 (en) * 2021-06-25 2024-11-07 Synaptive Therapeutics Llc Psilocybin analogs for treating psychological disorders
US20230064429A1 (en) 2021-08-19 2023-03-02 Mind Medicine, Inc. IMMEDIATE RELEASE FORMULATIONS OF d-LYSERGIC ACID DIETHYLAMIDE FOR THERAPEUTIC APPLICATIONS
US12492178B2 (en) 2021-09-01 2025-12-09 Empathbio, Inc. Stable polymorph of R-MDMA HCl
EP4396162A4 (fr) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc Allyl tryptamines asymétriques
US20230219955A1 (en) * 2021-09-20 2023-07-13 Betterlife Pharma Inc. Lsd derivatives, synthesis & method for treatment of diseases and disorders
EP4408412A4 (fr) * 2021-09-30 2025-07-16 ATAI Life Sciences AG Compositions et procédés de traitement de céphalées
WO2023086962A1 (fr) * 2021-11-12 2023-05-19 Terran Biosciences Inc. Psilocybine et o-acétylpsilocine, leurs sels et formes à l'état solide
US11912680B2 (en) 2021-12-28 2024-02-27 Empathbio, Inc. Nitric oxide releasing prodrugs of MDA and MDMA
CA3238440A1 (fr) 2021-12-30 2023-07-06 Atai Therapeutics, Inc. Analogues de dimethyltryptamine utilises en tant que medicaments d'administration d'oxyde nitrique
WO2023130075A2 (fr) 2021-12-31 2023-07-06 Empyrean Neuroscience, Inc. Organismes génétiquement modifiés pour produire des alcaloïdes psychotropes
US20250073207A1 (en) * 2022-01-12 2025-03-06 Eleusis Therapeutics Us, Inc. Psilocin benzoate formulation for intravenous infusion
WO2023168023A1 (fr) 2022-03-04 2023-09-07 Reset Pharmaceuticals, Inc. Co-cristaux ou sels comprenant de la psilocine
EP4499109A1 (fr) * 2022-03-25 2025-02-05 Ojai Energetics PBC Compositions psychédéliques et leurs procédés de formation
EP4514831A4 (fr) * 2022-04-27 2026-06-17 Hughes Howard Med Inst Récepteurs chimiogénétiques et leurs procédés de fabrication et d'utilisation
EP4522165A1 (fr) * 2022-05-13 2025-03-19 Reset Pharmaceuticals, Inc. Administration d'un composé psychédélique par injection sous-cutanée
CA3247344A1 (fr) 2022-06-09 2023-12-14 Diamond Therapeutics Inc. Psilocybine amorphe (a-polymorphe)
WO2023248222A1 (fr) * 2022-06-21 2023-12-28 Technion Research & Development Foundation Limited Agents modulateurs du récepteur 5-ht2c pour le traitement de troubles neurodégénératifs, mentaux, cognitifs et auto-immuns
US20240000795A1 (en) * 2022-06-30 2024-01-04 Terran Biosciences Inc. Methods and compositions relating to controlling psychedelic effects with serotonin receptor modulators
US12344583B2 (en) 2022-07-12 2025-07-01 Lobe Sciences Ltd. Solid psilocin salts
KR20250035567A (ko) * 2022-07-12 2025-03-12 로브 사이언시즈 엘티디. 안정된 실로신 염, 에스테르 및 접합체의 제조 및 이의 용도
WO2024019908A1 (fr) * 2022-07-19 2024-01-25 Lobe Sciences Ltd. Agent psychédélique sérotoninergique pour le traitement du mutisme sélectif
US12264131B2 (en) 2022-08-19 2025-04-01 Beckley Psytech Limited Pharmaceutically acceptable salts and compositions thereof
WO2024079648A1 (fr) * 2022-10-11 2024-04-18 Sintalica S.R.L. Système d'administration pour la libération contrôlée d'un composé psychédélique, composition pharmaceutique et utilisations associées
WO2024151625A1 (fr) * 2023-01-10 2024-07-18 Georgetown University Compositions de plga non toxiques et leurs procédés de fabrication et d'utilisation
CN121358470A (zh) * 2023-02-23 2026-01-16 布莱特西德公司 用于调节g蛋白偶联受体的组合物和方法
US12246005B2 (en) 2023-06-13 2025-03-11 Beckley Psytech Limited 5-methoxy-n,n-dimethyltryptamine (5-MeO-DMT) formulations
EP4739303A2 (fr) * 2023-07-03 2026-05-13 EmpathBio, Inc. Compositions d'énantiomère de mdma et méthodes de modulation de réponse aux agressions
WO2025024400A2 (fr) * 2023-07-21 2025-01-30 2A Biosciences, Inc. Tryptamines substituées et leurs utilisations
WO2025040932A1 (fr) * 2023-08-21 2025-02-27 Nechama Golan Guérison complète de toutes les maladies mentales à l'aide d'amide d'acide d-lysergique à différentes doses et durées de traitement
WO2026068690A1 (fr) * 2024-09-27 2026-04-02 Medichem, S.A. Injection à action prolongée de quétiapine

Family Cites Families (82)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LU36879A1 (fr) 1958-02-21
US3192111A (en) 1959-02-16 1965-06-29 Sandoz Ltd Method of inducing therapeutic tranquilization with psilocybin and psilocin
IL136023A0 (en) 1999-05-14 2001-05-20 Pfizer Prod Inc 5ht1 receptor agonists and either a cox-2 inhibitor or nsaid for the treatment of migraine
CA2422730A1 (fr) 2000-09-19 2002-03-28 Microbia, Inc. Modulation de production de metabolites secondaires par des proteines en bouquet binucleaire a zinc
US10738268B2 (en) 2016-08-21 2020-08-11 Insectergy, Llc Cannabis nanoemulsion methods
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
CA2537132A1 (fr) 2003-08-28 2005-03-10 Ranbaxy Laboratories Limited Chlorhydrate de valganciclovir amorphe
US9408405B2 (en) * 2003-10-03 2016-08-09 Veijlen N.V. Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
EP2240022B1 (fr) 2008-01-09 2016-12-28 Charleston Laboratories, Inc. Comprimés à deux couches contenant oxycodone et promethazine
WO2010123577A2 (fr) 2009-04-24 2010-10-28 Galenea Corp. Compositions et procédés pour évaluer des déficits cognitifs
US20120108510A1 (en) 2010-05-20 2012-05-03 Emory University Methods of improving behavioral therapies
EP2884888A4 (fr) 2012-08-16 2016-04-20 Ginger Io Inc Procédé de modélisation de changements de comportement et de santé
CN103778171A (zh) 2012-10-24 2014-05-07 I-昂索夫特有限公司 利用健康指数的健康媒体推荐系统
WO2014140925A2 (fr) 2013-03-10 2014-09-18 Peritech Pharma Ltd. Compositions topiques et procédés de traitement de troubles topiques
WO2014195032A1 (fr) 2013-06-07 2014-12-11 Medical Prognosis Institute A/S Procédés et dispositifs pour prédire une efficacité de traitement de fulvestrant chez des patients atteints de cancer
WO2016022462A1 (fr) * 2014-08-04 2016-02-11 University Of Georgia Research Foundation Inc. Nanoparticules thérapeutiques pour une accumulation dans le cerveau
US10570457B2 (en) 2014-09-26 2020-02-25 Medical Prognosis Institute A/S Methods for predicting drug responsiveness
DK3261640T3 (da) 2015-02-25 2022-07-11 Univ California 5ht-agonister til behandling af epilepsilidelser
EP3268086A4 (fr) 2015-03-10 2018-11-07 Eleusis Benefit Corporation, PBC Lsd pour le traitement de la maladie d'alzheimer
EP4173550A1 (fr) 2015-03-16 2023-05-03 Magic Leap, Inc. Diagnostic et de traitement de troubles de la santé
US10664572B2 (en) 2015-08-06 2020-05-26 Microsoft Technology Licensing, Llc Recommendations for health benefit resources
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
TW201822139A (zh) 2016-07-29 2018-06-16 嘉康利公司 用於動態產生個人的健康相關且客製化的建議之技術
US20190311789A1 (en) * 2016-10-03 2019-10-10 West Virginia University Computer implemented discovery of biomarkers for blood brain barrier disruption
US10596378B2 (en) 2016-10-18 2020-03-24 Joseph Rustick Method for treatment of depression using synaptic pathway training
NL2018190B1 (en) 2017-01-18 2018-07-26 Procare Beheer B V Psilocybin or psilocin in combination with cannabinoid
JP7273731B2 (ja) 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
US20190142851A1 (en) 2017-11-16 2019-05-16 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
CN108619214A (zh) * 2017-03-15 2018-10-09 王慎君 一种治疗肿瘤的药物
US20200147038A1 (en) 2017-04-20 2020-05-14 Eleusis Benefit Corporation, Pbc Assessing and treating psychedelic-responsive subjects
GB2571696B (en) 2017-10-09 2020-05-27 Compass Pathways Ltd Large scale method for the preparation of Psilocybin and formulations of Psilocybin so produced
WO2019079742A1 (fr) 2017-10-19 2019-04-25 Eleusis Benefit Corporation, Pbc Procédés et systèmes d'amélioration de la sécurité des pharmacothérapies psychédéliques
WO2019161050A1 (fr) 2018-02-18 2019-08-22 Akili Interactive Labs, Inc. Plateforme cognitive comprenant des éléments informatisés couplés à une thérapie contre les troubles de l'humeur
FI129102B (en) 2018-03-19 2021-07-15 Teknologian Tutkimuskeskus Vtt Oy Heterological production of psilosybin
EP3813810A4 (fr) 2018-06-21 2022-03-30 Robert John Petcavich Procédé d'induction de la genèse dendritique et synaptique dans des maladies neurodégénératives chroniques
US12090145B2 (en) 2018-08-20 2024-09-17 Yale University Combination therapy for treating or preventing depression or other mood diseases
EP3675137A1 (fr) 2018-12-27 2020-07-01 Telefonica Innovacion Alpha S.L Procédé et système d'estimation et d'amélioration du bien-être plus efficaces
CA3125439A1 (fr) 2019-01-04 2020-07-09 Apollo Neuroscience, Inc. Systemes et procedes de generation d'ondes pour vibration transcutanee
MX2021009037A (es) * 2019-01-30 2021-10-13 Diamond Therapeutics Inc Composiciones y metodos para el manejo de trastornos.
US12616706B2 (en) 2019-03-07 2026-05-05 Arbormentis LLC Compositions and methods of use comprising substances with neural plasticity actions administered at non-psychedelic/psychotomimetic dosages and formulations
KR20220008824A (ko) 2019-04-17 2022-01-21 컴퍼스 패쓰파인더 리미티드 실로시빈으로 불안 장애, 두통 장애 및 섭식 장애를 치료하는 방법
WO2021003467A1 (fr) 2019-07-04 2021-01-07 Sw Holdings, Inc. Compositions de dosage et procédés d'utilisation de composés psychédéliques
US11766445B2 (en) 2019-07-18 2023-09-26 Concept Matrix Solutions Oral soft gel capsule containing psychedelic compound
GB201911024D0 (en) 2019-08-01 2019-09-18 Beckley Found Compounds for use in a method of treating or preventing neurological and/or psychiatric disorders
GB201911095D0 (en) 2019-08-02 2019-09-18 Randox Laboratories Ltd Biological status classification
WO2021030571A1 (fr) 2019-08-13 2021-02-18 University Of Maryland, Baltimore Méthodes de traitement de troubles psychologiques et cérébraux
JP2022549488A (ja) 2019-09-25 2022-11-25 ヤンセン ファーマシューティカルズ，インコーポレーテッド 投与量レジメン及び構成成分の互換性を確立するための薬物投与デバイス及びシステム
WO2021072530A1 (fr) 2019-10-15 2021-04-22 Tassili Life Sciences, Corp. Formulations à libération contrôlée d'agents dérivés de psilocybes et leur procédé d'utilisation, et procédés et compositions pour traiter une lésion cérébrale traumatique légère avec un syndrome de stress post-traumatique
US20230021957A1 (en) 2019-12-04 2023-01-26 Neonmind Biosciences Inc. Use of psilocin, psilocybin or analogs thereof in weight loss, treatment of obesity and compulsive eating disorder
US20210236523A1 (en) 2020-02-05 2021-08-05 Yale University Psychedelic treatment for headache disorders
IL295671A (en) 2020-02-28 2022-10-01 Universit?Tsspital Basel Controlling effects after 5ht2a agonists administration
CN115916173A (zh) 2020-04-13 2023-04-04 巴塞尔大学医院 Lsd剂量鉴定
AU2021267101B2 (en) 2020-05-05 2024-03-28 Universitätsspital Basel MDMA treatment to enhance acute emotional effects profile of LSD, psilocybin or other psychedelics
AU2021292943B2 (en) 2020-06-15 2024-04-04 Universitätsspital Basel MDMA response prediction
AU2021311493A1 (en) 2020-07-24 2023-03-16 Mindset Pharma Inc. Scalable synthetic route for psilocin and psilocybin
EP4188382A4 (fr) 2020-07-29 2024-08-14 The Royal Institution for the Advancement of Learning / McGill University Administration de modulateurs de récepteurs de 5-ht et/ou d'ampa pour le traitement d'affections neurologiques
WO2022023812A1 (fr) 2020-07-29 2022-02-03 Diamond Therapeutics Inc. Agonistes de récepteur 5-ht à libération prolongée pour des affections neurologiques
CA3188263A1 (fr) 2020-08-05 2022-02-10 Matthias Emanuel LIECHTI Procede d'administration de dmt intraveineux pour psychotherapie assistee par dmt
AU2021382158C1 (en) 2020-11-18 2026-05-07 Definium Therapeutics US, Inc. Mdma prodrugs to assist psychotherapy
US20220273628A1 (en) 2021-02-19 2022-09-01 Universitätsspital Basel Effects of lysergic acid diethylamide (lsd) and of lsd analogs to assist psychotherapy for generalized anxiety disorder or other anxiety not related to life-threatening illness
US20220267252A1 (en) 2021-02-24 2022-08-25 Mind Medicine, Inc. Mescaline derivatives with modified action
US20220265582A1 (en) 2021-02-24 2022-08-25 Universitätsspital Basel Effects of mescaline and of mescaline analogs (scalines) to assist psychotherapy
BR112023017866A2 (pt) 2021-03-06 2023-10-10 Univ Basel Método de dosagem de lsd no tratamento de pacientes, método para determinar uma dose preferida de lsd e método para determinar uma dose de lsd com base na avaliação da presença de inibidores de cyp2d6
EP4304603A4 (fr) 2021-03-08 2025-01-22 Diamond Therapeutics Inc. Titrage d'agonistes du récepteur sérotoninergique
CN117177959A (zh) 2021-03-18 2023-12-05 赛本爱尔兰有限公司 裸头草碱类似物、盐、组合物和使用方法
US20220323405A1 (en) 2021-04-08 2022-10-13 Universitätsspital Basel Combination product using 3,4-methylenedioxymethamphetamine and carvedilol for the treatment of psychiatric disorders
EP4792879A2 (fr) 2021-05-17 2026-08-19 Cybin IRL Limited Formulations de psilocybine
US11801256B2 (en) 2021-06-08 2023-10-31 Universitätsspital Basel Antidepressant-psilocybin co-treatment to assist psychotherapy
WO2023012524A2 (fr) 2021-08-03 2023-02-09 Universitatsspital Basel Détermination d'équivalence de dose de lsd et psilocybine
EP4392402A4 (fr) 2021-08-24 2025-07-09 Mind Medicine Inc Voies de synthèse pour accéder à des promédicaments de mdma à l'aide d'intermédiaires contrôlés et non contrôlés
CA3133547C (fr) 2021-10-07 2024-07-02 Psilo Scientific Ltd. Extraction liquide-liquide d'alcaloides psychoactifs purifies
US20230233688A1 (en) 2021-11-04 2023-07-27 Mind Medicine, Inc. Mdma prodrugs to assist psychotherapy
WO2023091437A1 (fr) 2021-11-17 2023-05-25 Mind Medicine, Inc. Dérivés de désoxyscaline ayant une action de type mécaline modifiée
US20230285327A1 (en) 2021-11-17 2023-09-14 Mind Medicine, Inc. Desoxyscaline derivatives with modified mescaline-like action
CA3242786A1 (fr) 2022-01-07 2023-07-13 Universitatsspital Basel R-mdma et s-mdma pour aider la psychotherapie
US20240307345A1 (en) 2022-01-07 2024-09-19 Universitatsspital Basel R-MDMA and S-MDMA TO ASSIST PSYCHOTHERAPY
US20250182901A1 (en) 2022-03-07 2025-06-05 Diamond Therapeutics Inc. Systems and methods for affecting well-being
US20250176904A1 (en) 2022-05-23 2025-06-05 Diamond Therapeutics Inc. Pre-dosing method of assessing drug benefits in patients
CA3247344A1 (fr) 2022-06-09 2023-12-14 Diamond Therapeutics Inc. Psilocybine amorphe (a-polymorphe)
CN119923261A (zh) 2022-06-20 2025-05-02 思维医学股份有限公司 具有改良的lsd样作用的麦角酸衍生物
WO2024118280A1 (fr) 2022-11-30 2024-06-06 Mind Medicine, Inc. Dérivés de 4-alcényle et de 4-alcynyle phénéthylamine et composés associés ayant une action de type dom modifiée
WO2024263978A1 (fr) 2023-06-22 2024-12-26 Mind Medicine, Inc. Phénéthylamines de type allyle et propargylamine et tryptamines pour traitement de troubles médicaux

Also Published As

Publication number Publication date
JP2022523700A (ja) 2022-04-26
IL285186A (en) 2021-09-30
AU2020215150A1 (en) 2021-09-09
AU2025203049A1 (en) 2025-05-22
CN114040767A (zh) 2022-02-11
KR20210134313A (ko) 2021-11-09
WO2020157569A1 (fr) 2020-08-06
US12691130B2 (en) 2026-07-28
AU2020215150B8 (en) 2025-07-03
US20230113351A1 (en) 2023-04-13
AU2020215150A8 (en) 2025-07-03
MX2021009037A (es) 2021-10-13
MX2025007468A (es) 2025-07-01
AU2020215150B2 (en) 2025-02-06
EP3917537A1 (fr) 2021-12-08
EP3917537A4 (fr) 2022-09-07
US20260053831A1 (en) 2026-02-26
US20220096504A1 (en) 2022-03-31
US20260053829A1 (en) 2026-02-26
CA3127854A1 (fr) 2020-08-06
BR112021014750A2 (pt) 2021-09-28
JP2025186241A (ja) 2025-12-23

Similar Documents

Publication Publication Date Title
EP3917537A4 (fr) Compositions et méthodes comprenant un agoniste de récepteur 5ht destinées au traitement de troubles psychologiques, cognitifs, comportementaux et/ou d'humeur
MA54229A (fr) Composés et compositions destinés au traitement d'états pathologiques associés à une activité de nlrp
MA30339B1 (fr) Azolopyrimidines inhibitrices de l'activite du recepteur cannabinoïde 1
EA202190661A1 (ru) Агонисты фарнезоидного х-рецептора для лечения заболевания
EP3876712A4 (fr) Modèles d'animaux, procédés de criblage, et procédés de traitement pour maladies ou troubles intraoculaires
EP3755318A4 (fr) Des plantes de cannabis sativa génétiquement modifiées et des composés cannabinoïdes modifiés pour le traitement de la toxicomanie et d'autres troubles
MA52631A (fr) Compositions et méthodes pour le traitement de la maladie de parkinson
MA52778A (fr) Méthodes de traitement de troubles associés au récepteur s1p1
MA53739A (fr) Composition et son utilisation pour le traitement de la maladie de parkinson et de troubles apparentés
EP3927706A4 (fr) Composés d'imidazopyridinyle et leur utilisation pour le traitement de troubles prolifératifs
EP3934646A4 (fr) Compositions pharmaceutiques pour le traitement de maladies ou de troubles oculaires
EP3952840A4 (fr) Compositions pharmaceutiques et méthodes de traitement de troubles mentaux, comportementaux et cognitifs
BRPI0511527A (pt) compostos e composições como moduladores de ppar
EP3504204A4 (fr) Indazolyl-l,2,4-thiadiazolamines et composés apparentés pour l'inhibition de protéine kinase associée à rho et le traitement de la maladie
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
EP3969009C0 (fr) Beta-1,3'-galactosyllactose destiné au traitement des troubles de la barrière intestinale
EP1784191A4 (fr) Traitement de troubles psychologiques ou cognitifs employant un hypocholestérolémiant associé à un antidépresseur
EP4216979A4 (fr) Méthodes de traitement de troubles associés à la voie d'un récepteur de la mélanocortine-4
EP3943107A4 (fr) Composition pour prévenir ou traiter une maladie du cerveau et du système nerveux
EP3866799A4 (fr) Compositions et méthodes permettant de traiter la maladie d'ehlers-danlos et les troubles associés
BRPI0510024A (pt) compostos e composições como modulares de ppar
MA51679A (fr) Composés destinés au traitement de troubles dépendant de la kinase
ATE503474T1 (de) Endocannabinoid-ähnliche verbindungen und deren verwendung zur behandlung von dermatitis
EP3946433A4 (fr) Compositions, dispositifs et méthodes de traitement de la maladie de fabry
DE602005026543D1 (de) Zusammensetzungen und verfahren zur behandlung kognitiver störungen